Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion type Assertion NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_head.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion description "[Therapeutic inhibitors of HER3 should be considered as part of multidrug combinations aimed at completely and rapidly disabling the HER2 network in HER2-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion evidence source_evidence_literature NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion SIO_000772 23224399 NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion wasDerivedFrom befree-20150227 NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.
- NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_assertion wasGeneratedBy ECO_0000203 NP380620.RAa7j0Tx-VPRdJZZbx6vze3y1bPlmxF7q1GNUA5kvj2X8130_provenance.